OBJECTIVE: To investigate the efficiency and safety of callispheres beads loaded with donafenib (DCBs) for embolization in a VX2 liver tumor, as well as the improvement of tumor angiogenesis following embolization. METHODS: Forty New Zealand white rabbit VX2 liver tumors were treated with four different drugs via the hepatic artery: NS (normal saline), CB (blank callispheres beads), ACB (adriamycin-loaded callispheres beads) and DCB (DCBs). Hematoxylin-eosin staining was performed to assess tumor necrosis, while MRI was employed to detect the changes in tumor size. The safety was evaluated by the liver and kidney function parameters, and the immunofluorescence and immunohistochemical staining were performed to reflect the tumor hypoxia and tumor angiogenesis following embolization. RESULTS: The DCB group had the smallest tumor growth rate, but the tumor necrosis rate was the highest of the four groups. Compared to the CB and ACB groups, the DCB group did not aggravate the liver damage and had no influence on kidney function. The staining results showed that, although the tumor hypoxia deteriorated after DCBs embolization, the expression of VEGF (vascular endothelial growth factor) reduced, thus inhibiting tumor angiogenesis. CONCLUSION: DCB administration via hepatic artery is an effective and safe treatment for a preclinical liver cancer model, with the unique benefit of suppressing tumor angiogenesis following embolization.
OBJECTIVE: To investigate the efficiency and safety of callispheres beads loaded with donafenib (DCBs) for embolization in a VX2 liver tumor, as well as the improvement of tumor angiogenesis following embolization. METHODS: Forty New Zealand white rabbit VX2 liver tumors were treated with four different drugs via the hepatic artery: NS (normal saline), CB (blank callispheres beads), ACB (adriamycin-loaded callispheres beads) and DCB (DCBs). Hematoxylin-eosin staining was performed to assess tumor necrosis, while MRI was employed to detect the changes in tumor size. The safety was evaluated by the liver and kidney function parameters, and the immunofluorescence and immunohistochemical staining were performed to reflect the tumor hypoxia and tumor angiogenesis following embolization. RESULTS: The DCB group had the smallest tumor growth rate, but the tumor necrosis rate was the highest of the four groups. Compared to the CB and ACB groups, the DCB group did not aggravate the liver damage and had no influence on kidney function. The staining results showed that, although the tumor hypoxia deteriorated after DCBs embolization, the expression of VEGF (vascular endothelial growth factor) reduced, thus inhibiting tumor angiogenesis. CONCLUSION: DCB administration via hepatic artery is an effective and safe treatment for a preclinical liver cancer model, with the unique benefit of suppressing tumor angiogenesis following embolization.
Authors: Ahmad Parvinian; Leigh C Casadaban; Zane Z Hauck; Richard B van Breemen; Ron C Gaba Journal: Diagn Interv Radiol Date: 2015 May-Jun Impact factor: 2.630
Authors: Carolyn D Britten; Antoinette S Gomes; Zev A Wainberg; David Elashoff; Rafael Amado; Yan Xin; Ronald W Busuttil; Dennis J Slamon; Richard S Finn Journal: BMC Cancer Date: 2012-01-14 Impact factor: 4.430
Authors: Asis Palazon; Petros A Tyrakis; David Macias; Pedro Veliça; Helene Rundqvist; Susan Fitzpatrick; Nikola Vojnovic; Anthony T Phan; Niklas Loman; Ingrid Hedenfalk; Thomas Hatschek; John Lövrot; Theodoros Foukakis; Ananda W Goldrath; Jonas Bergh; Randall S Johnson Journal: Cancer Cell Date: 2017-11-13 Impact factor: 31.743